WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Difference”. Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD). See the Sustainability section of Repligen’s website for more information.
Tony Hunt, Chief Executive Officer at Repligen said, “Our initial Sustainability report published in 2021 elevated awareness in the company and prompted higher levels of action across the ESG spectrum. We saw strong ratings and rankings as a result and are pleased to share this next 2022 progress report, while continuing to work toward positively impacting some of our more challenging initiatives and collaboration-based goals.”
Dianne Heiler, Senior Director of Packaging and Head of Sustainability at Repligen said, “I’m proud to be part of the team at Repligen that is driving progress across multiple sustainability ambitions, with the full support and participation of our executive team and Board. As this report publishes, already we are expanding the scope of our efforts and will submit a commitment letter by year end 2023 to SBTi* to lower total GHG emissions in alignment with the latest climate science.”
Below are just a few of the 2022 Sustainability Report highlights. Report data is through year end 2022 unless otherwise noted.
Environmental impacts:
Social impacts:
Governance impacts:
Survey participation:
*SBTi: Science Based Targets initiative
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information, please visit www.repligen.com, and follow us on LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$149.19 |
Daily Change: | 3.54 2.43 |
Daily Volume: | 175,836 |
Market Cap: | US$8.360B |
December 09, 2024 November 12, 2024 November 05, 2024 July 30, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB